Peakdale Molecular launches new website

Peakdale's full range of products, including Peakexplorer GPCR libraries, Peakfinder chemogenetic arrays for drug discovery, unique intermediates and screening compounds are described

Over the past six months, Peakdale Molecular has substantially expanded its medicinal chemistry capabilities and range of products and services for its pharmaceutical and biotechnology customers.

The extended medicinal chemistry services has been specifically designed to complement customers' drug discovery initiatives through hit-to-lead and lead optimisation projects, patent protection projects, back-up chemotypes and fast follower candidate programmes.

Peakdale's full range of products, including Peakexplorer GPCR libraries, Peakfinder chemogenetic arrays for drug discovery, unique intermediates and screening compounds are also described in the new website.

"Working with leading biotechs and 18 of the world's top 20 pharma companies has enabled us to extend our service offering based on feedback from them." commented Kim Morrison, CEO of Peakdale Molecular.

These customers have an ever increasing need to accelerate their drug discovery initiatives and reduce failure rates during development.

Our new products and services have been specifically designed to complement our existing range in order to meet this challenge.

Peakdale Molecular was founded in 1992.

Today, the company's customers include 18 of the top 20 global pharmaceutical companies and an increasing number of biotechnology companies.

Its teams of chemists combine experience in pharmaceutical R+D and process development, medicinal chemistry, parallel synthesis and fine chemicals to deliver unique chemistry solutions to a range of drug discovery challenges.

Peakdale has earned a reputation from its customers for the highest quality of service through its responsiveness, dedication and rapid turnaround.

The company says it also has a reputation for maintaining the highest standards of confidentiality and helping customers to establish ownership of intellectual property.

Application of less commonly used chemistry, including high temperature/pressure reactions, proprietary heterocyclic chemistry and nucleoside synthesis, enables Peakdale's chemists to generate unique compounds for drug discovery.

Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research.

Back to top